DRUG-MONOCLONAL ANTIBODY CONJUGATES FOR CANCER-THERAPY - POTENTIALS AND LIMITATIONS

被引：0
|
作者：
PIMM, MV
机构：
来源：
CRC CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS | 1988年 / 5卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：189 / 227
页数：39
相关论文
共 50 条
  • [31] SPECIFIC ACTIVATION OF GLUCURONIDE PRODRUGS BY ANTIBODY-TARGETED ENZYME CONJUGATES FOR CANCER-THERAPY
    WANG, SM
    CHERN, JW
    YEH, MY
    NG, YC
    TUNG, E
    ROFFLER, SR
    CANCER RESEARCH, 1992, 52 (16) : 4484 - 4491
  • [32] MONOCLONAL-ANTIBODIES IN CANCER-THERAPY
    MELLSTEDT, H
    CURRENT OPINION IN IMMUNOLOGY, 1990, 2 (05) : 708 - 713
  • [33] MONOCLONAL-ANTIBODIES IN CANCER-THERAPY
    FAVROT, MC
    COMBARET, V
    PHILIP, T
    PATHOLOGIE BIOLOGIE, 1989, 37 (02): : 99 - 100
  • [34] MONOCLONAL-ANTIBODIES IN CANCER-THERAPY
    OLDHAM, RK
    JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (09) : 582 - 590
  • [35] MONOCLONAL-ANTIBODIES FOR CANCER-THERAPY
    CATANE, R
    LONGO, DL
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1988, 24 (9-10): : 471 - 476
  • [36] MONOCLONAL-ANTIBODIES IN CANCER-THERAPY
    ISSELL, BF
    GROVES, ES
    YOUNG, JD
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 178 - 178
  • [37] MONOCLONAL-ANTIBODIES IN CANCER-THERAPY
    ROWE, PM
    LANCET, 1994, 344 (8932): : 1288 - 1288
  • [38] Erratum: Development of potent monoclonal antibody auristatin conjugates for cancer therapy
    Svetlana O Doronina
    Brian E Toki
    Michael Y Torgov
    Brian A Mendelsohn
    Charles G Cerveny
    Dana F Chace
    Ron L DeBlanc
    R Patrick Gearing
    Tim D Bovee
    Clay B Siegall
    Joseph A Francisco
    Alan F Wahl
    Damon L Meyer
    Peter D Senter
    Nature Biotechnology, 2003, 21 : 941 - 941
  • [39] THE LIMITATIONS OF CANCER-THERAPY - IS CANCER PREVENTION A REALISTIC ALTERNATIVE
    RAZIS, DV
    JOURNAL OF CHEMOTHERAPY, 1993, 5 : 639 - 640
  • [40] Potential of antibody-drug conjugates (ADCs) for cancer therapy
    Marei, Hany E.
    Cenciarelli, Carlo
    Hasan, Anwarul
    CANCER CELL INTERNATIONAL, 2022, 22 (01)
12345